Management and Prevention of Nausea and Vomiting Supportive Care

Arrhythmia Risk Leads to Label Change for Zofran (07-9-2012)

Interim data from a recent clinical trial has indicated that a 32 mg single dose of ZofranĀ® (ondansetron) may affect the electrical activity of the heart and could predispose patients to develop an abnormal heart rhythm. The U.S. Food and Drug Administration... Continue Reading